HLA-DR polymorphism and primary biliary cirrhosis: evidence from a meta-analysis

Related Experiment Video

Updated: May 1, 2026

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

12.4K

Man Li1, Hao Zheng2, Qing-bao Tian1

  • 1Department of Epidemiology and Statistics, School of Public Health, Hebei Medical University, Shijiazhuang, China.

Archives of Medical Research
|March 25, 2014
PubMed

Insights

Human Leukocyte Antigen (HLA) DR *7 and *8 allele polymorphisms increase primary biliary cirrhosis (PBC) risk. Conversely, HLA-DR *11, *12, *13, and *15 alleles appear protective in specific populations, according to this meta-analysis.

Area of Science:

  • Immunogenetics
  • Autoimmune Diseases
  • Genetic Epidemiology

Background:

  • Primary biliary cirrhosis (PBC) is a chronic autoimmune liver disease with a complex etiology.
  • Human Leukocyte Antigen (HLA) genes, particularly HLA-DR, are strongly associated with autoimmune diseases.
  • Understanding the specific HLA-DR polymorphisms involved in PBC susceptibility is crucial for disease pathogenesis research.

Purpose of the Study:

  • To quantitatively analyze the association between specific human leukocyte antigen (HLA) DR polymorphisms and the susceptibility to primary biliary cirrhosis (PBC).
  • To consolidate evidence from multiple studies to provide a robust assessment of genetic risk factors for PBC.

Main Methods:

  • A comprehensive literature search was conducted for studies investigating HLA-DR polymorphisms and PBC susceptibility up to June 2013.
  • Meta-analysis was employed to calculate odds ratios (OR) and confidence intervals (CI) for various HLA-DR alleles.
  • Statistical analyses were performed using Stata 11.0 software to assess the significance of associations.

Main Results:

  • Nineteen articles, representing 20 studies, were included in the meta-analysis.
  • HLA-DR *7 and *8 alleles showed a significant association with increased PBC susceptibility across different ethnic populations (Asian, European, American).
  • HLA-DR *11, *12, *13, and *15 alleles demonstrated a protective effect in specific populations, with notable associations in Asian and European groups.

Conclusions:

  • The meta-analysis confirms that HLA-DR *7 and *8 allele polymorphisms are significant risk factors for developing primary biliary cirrhosis.
  • Certain HLA-DR allele polymorphisms, including *11, *12, *13, and *15, act as protective factors against PBC in specific ethnic groups.
  • These findings highlight the critical role of HLA-DR genetic variations in the immunopathogenesis of primary biliary cirrhosis.
Abstract

Keywords:
HLAMeta-analysisPolymorphismPrimary biliary cirrhosis

More Related Videos

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms11:36

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

2.5K
Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

2.4K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
382
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
358